Journals / Turkish Journal of Biology / 2021 / Cilt: 45 - Sayı: 6

Identifying specific matrix metalloproteinase-2-inhibiting peptides through phage display-based subtractive screening

Pages
674–682
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Furthermore, our findings suggest that our substractive biopanning screening method is a suitable strategy for identifying peptides that selectively inhibit MMP-2.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Gelatinases A and B, which are members of the matrix metalloproteinase(MMP) family, play essential roles in cancer development and metastasis, as they can break down basal membranes.
📊
Key Findings & Data:In this study, subtractive panning was carried out using a 12-mer peptide library to identify peptides that block gelatinase A activity (MMP-2), which is a key pharmacological target.
💡
Conclusion & Impact:Furthermore, our findings suggest that our substractive biopanning screening method is a suitable strategy for identifying peptides that selectively inhibit MMP-2.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Gelatinases A and B, which are members of the matrix metalloproteinase(MMP) family, play essential roles in cancer development and metastasis, as they can break down basal membranes. Therefore, the determination and inhibition of gelatinases is essential for cancer treatment. Peptides that can specifically block each gelatinase may, therefore, be useful for cancer treatment. In this study, subtractive panning was carried out using a 12-mer peptide library to identify peptides that block gelatinase A activity (MMP-2), which is a key pharmacological target. Using this method, 17 unique peptide sequences were determined. MMP-2 inhibition by these peptides was evaluated through zymogram analyses, which revealed that four peptides inhibited MMP-2 activity by at least 65%. These four peptides were synthesized and used for in vitro wound healing using human umbilical vein endothelial cells, and two peptides, AOMP12 and AOMP29, were found to inhibit wound healing by 40%. These peptides are, thus, potential candidates for MMP2 inhibition for cancer treatment. Furthermore, our findings suggest that our substractive biopanning screening method is a suitable strategy for identifying peptides that selectively inhibit MMP-2.

🔖

Cite This Article

IŞIK, Ş., ERDAĞ, B., BAHADIR, A. Ö., BALCIOĞLU, B. K., SERHATLI, M. (2022). Identifying specific matrix metalloproteinase-2-inhibiting peptides through phage display-based subtractive screening. Turkish Journal of Biology, Cilt: 45 - Sayı: 6, 674–682. https://ajindex.com/articles/600096

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Atkinson SJ, English JL, Holway N, Murphy G (2004). Cellular cholesterol regulates MT1 MMP dependent activation of MMP 2 via MEK-1 in HT1080 fibrosarcoma cells. FEBS Letters 566 (1–3): 65–70. doi: 10.1016/j.febslet.2004.04.040 Bahadir AO, Balcioglu BK, Uzyol KS, Hatipoglu I, Sogut I et al. (2011). Phage displayed HBV core antigen with immunogenic activity. Applied Biochemistry and Biotechnology 165 (7–8): 1437–1447. doi: 10.1007/s12010-011-9365-1
  2. Cao Y (2001). Endogenous angiogenesis inhibitors and their therapeutic implications. International Journal of Biochemistry and Cell Biology 33 (4): 357–369. doi: 10.1016/S1357- 2725(01)00023-1
  3. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T (2003). Regulation of matrix metalloproteinases. An overview. Molecular and Cellular Biochemistry 253 (1–2): 269–285. doi: 10.1023/A:1026028303196 Cieplak P, Strongin AY (2017). Matrix metalloproteinases – From the cleavage data to the prediction tools and beyond. In Biochimica et Biophysica Acta - Molecular Cell Research 1864 (11): 1952– 1963. doi: 10.1016/j.bbamcr.2017.03.010 Deryugina EI, Quigley JP (2006). Matrix metalloproteinases and tumor metastasis. Cancer and Metastasis Reviews 25 (1): 9–34. doi: 10.1007/s10555-006-78869
  4. Dufour A, Overall CM (2013). Missing the target: Matrix metalloproteinase antitargets in inflammation and cancer. In Trends in Pharmacological Sciences 34 (4): 233–242. doi: 10.1016/j.tips.2013.02.004 Erdag B, Balcioglu BK, Bahadir AO, Serhatli M, Kacar O et al. (2011). Identification of novel neutralizing single-chain antibodies against vascular endothelial growth factor receptor 2. Biotechnology and Applied Biochemistry 58 (6): 412–422. doi: 10.1002/bab.61 Giannopoulos G, Pavlakis K, Parasi A, Kavatzas N, Tiniakos D (2008). The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters. Anticancer Research 28 (3B): 1875–1882.
  5. Guruvayoorappan C, Kuttan G (2008). Amentoflavone inhibits experimental tumor metastasisthrough a regulatory mechanism involving MMP-2, MMP-9, prolyl hydroxylase, lysyl oxidase,VEGF, ERK-1, ERK-2, STAT1, nm23 and cytokines in lung tissues of C57BL/6 mice. Immunopharmacology and Immunotoxicology 30 (4): 711– 727. doi: 10.1080/08923970802278276 Huang H (2018). Matrix metalloproteinase-9 (MMP-9) as a cancer biomarker and MMP-9 biosensors: Recent advances. In Sensors (Switzerland) 18 (10): 324